Outcome of the Meeting of the Board of Director of Bharat Parenterals Limited held on October 29, 2026

Date: October 29, 2026 Secretary Listing Department BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001. Script Code: 541096 SUB: OUTCOME OF THE BOARD MEETING. Dear Sir/Madam, Pursuant to Regulation 30, 33 and other related Regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and with reference to the captioned subject, we hereby inform that, the board of directors, at their meeting held today i.e. October 29, 2026, have inter-alia: 1. Approved and took on record the Un-audited Standalone and Consolidated Financial Results as per Indian Accounting Standards (IND AS) along-with the Limited Review Report and Management Discussion and Analysis Report for the quarter and half year ended September 30, 2026; The meeting of Board of Directors commenced at 03:00 p.m. and concluded at 04:00 p.m. We are enclosing herewith the financial results for your information and record. The same will be made available on the Company's website at www.bplindia.in Request you to please take the same on record. Thanking You, FOR BHARAT PARENTERALS LIMITED, Mr. Sharmin Soni Company Secretary & Compliance Officer ICSI Membership No: A-75694 o GF, 1"& 2^o Floor, prasanna House, Associated Society, ffi Opp. Radhakrishna Park, Nr. Akota Stadium, Akota, Vadodara - 39OO2O IND o: 0265-3s99941 / 2331060 O : +91-91732-02343 / +91_6j552_89986 offi ce @ s m b-co. co m @ : www. sm b-co. com CHARTERED ACCOUNTANTS Independent Auditor's Review Report on Quarterly and Year to Date Unaudited Standalone Financial Results of Bharat Parenterals Limited pursuant to the Regulation 33 of the sEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as amended. The Board of Directors Bharat Parenterals Limited L We have reviewed the accompanying statement of unaudited standalone financial results ('the Statement') of Bharat Parenterals Limited ('the Company') for the quarter ended on 30m September 2026, and year to date from 0l't April, 2026, to 30th Septemb er,2026 (.the statement,,) attached being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. (the ,,Listing Regulations"). 2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting,' prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company, our responsibility is to express a conclusion on the Statement based on our review. J. We conducted our review of the statement in accordance with Standards on Review Engagement (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement' A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Ac! 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. In our opinion and to the best of our information and according to the explanations given to us, the Statement Based on our review conduct above, nothing has come to our attention that causes us to believe the accompanying Statement, prepared in accordance with the recognition and measurement Vadodara Page 1 of 2 Shah Mehta & Bakshi Chartered Accountants principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act,2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement. For Shah Mehta & Firm Registration Membership No.: 177342 UDIN : 261 7 7 3 42Y AUUWA95 3 7 Vadodara, October 29, 2026 Page 2 of 2 BHARAT PARENTERALS LIMITED Regd. Office: Viii Haripura, TA Savli, District: Vadodara - 391 520 CIN:L24231GJ1992PLC018237 Website: www.bplindia.in STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2026 Rs In Lakhs Quarter Ended Half Year En'ded Year Ended Particular 30.09.2026 30.06.2026 30.09.2025 30.09.2026 30.09.2025 31.03.2026 (Unaudited) (Unaudited) (UnaudltedJ (Unaudited) (Unaudited) (Audited) 1 A. Revenue from operations 7,855.44 5,550.10 4,169.58 13,405.54 13,606.47 23,401.48 B. Other Income 295.36 105.30 421.18 400.66 583.23 1 255.23 Total Income 8 150.81 5 655.40 4 590.77 13 806'.20 14 189.70 24 656.71 2 Expenses A. Cost of materials consumed 4,887.33 3,269.39 3,127.89 8,156.72 8,610.76 14,889.94 B. Purchaseo f Stock-in-Trade 254.22 103.95 - 358.18 - 100.14 C. Changesin inventories of finished goods, work-in-progress and (21.36) (31.03) (796.63) (52.39) 3.82 205.47 stock-in-trade D. Employeeb enefit expense 728.39 648.01 650.58 1,376.40 1,246.66 2,513.13 E. Finance costs . 62.42 69.33 95.51 131.75 237.24 343.51 F. Depreciation, depletion and amortisation expense 232.04 225.50 216.59 457.54 422.42 836.45 G. Other Exoenses 1 302.65 877.20 954.82 2 179.85 1 986.84 3 583.81 Total exoenses - 7 445.70 5 162.35 4 248.77 12 608.0S 12 507.74 22 472.44 3 Total profit before tax 705.11 493.0S 342.00 1,198.16 1,681.95 2,184.27 4 Tax expense Current tax 197.99 156.55 114.32 354.53 484.77 660.35 Deferred tax (34.89) (29.21) (45.04) (64.10) (75.49) (113.44) Short I (Excess) orovision of tax in resoect of earlier years 35.45 Total tax exoenses 163.10 127.34 69.28 290.44 409.28 582.37 5 Net Profit I (loss) for oeriod 542.01 365.71 272.72 907.72 1 272.67 1 601.90 6 Other comprehensive Income Items that will not be reclassified to profit or loss Remeasuremenot f defined benefit obligation 6.23 6.23 8.67 12.47 4.02 24.93 Incomet ax relatina to Remeasuremento f Defined benefit clans (1.57) (1.57) (2.18) (3.14) (1.01) (6.28) Other comorehenslve Income for the vear net of taxes 4.66 4.66 6.49 9.33 3.01 18.66 7 Total Comorehensive Income for the oeriod 546.67 370.37 279.20 917.0S 1 275.68 1 620.SS 8 Paid up Equity Share Capital (FaceV alue of Rs 10/- per share) 689.20 689.20 9 Other Equity 40,393.23 39,545.10 10 Earningsp er share (not annualised, except for March 31, year ended amount) Basic (Rs.) 7.86 5.31 3.96 13.17 18.47 23.24 Diluted (Rs.I 7.86 5.31 3.96 13.17 18.47 23.24 See accompanying notes to the standalone Financial Results 1 The above unaudited financial results for the quarter and half year ended September 30, 2026 have been duly reviewed by Statutory auditors, recommended by the Audit Committee and have been approved and were taken on record by the Board of Directors at its meeting held on October 29, 2026. The Companyh as only one segment of activity, namely "Pharmaceuticals". 3 A ddi tiona I in f ormation f or t h e investor are orovi d e d h ereund er: R s. I n L ak h s Particulars Quarter Ended Half Year Ended Year Ended 30.09.2026 30.06.2026 30.09.2025 30.09.2026 30.09.2025 31.03.2026 EBITDA (In Fi11ures) includina other income 999.57 787.88 654.11 1,787.45 2,341.61 3,364.23 EBITDA (In Fieuresl excluding other income 704.21 682.58 232.93 1,386.78 1,758.38 2,109.00 EBI [Showing first 8,000 characters — download PDF for full document]